Table 2 Serum FT3 at different times after treatment
n | 4w | 8w | 12w | |||||
|---|---|---|---|---|---|---|---|---|
FT3 (pmol/L) | Normalization [(n(%)] | FT3 (pmol/L) | Normalization [(n(%)] | FT3 (pmol/L) | Normalization [(n(%)] | |||
Group A (mild group, lower dose) | 78 | 6.2(5.2–7.1) | 61(78.2%) | 5.9(5.3–6.7) | 70(89.7%) | 5.9(5.3–6.6) | 71(91.0%) | |
Group B (moderate group, higher dose) | 37 | 8.9(5.7–13.2) | 16(43.2%) | 6.5(5.4–7.7) | 28(75.7%) | 5.6(4.9–6.9) | 29(78.4%) | |
Group C (severe group, higher dose) | 24 | 10.0(7.4–17.4) | 6(25.0%) | 6.2(4.9–6.9) | 18(75.0%) | 6.1(5.6–6.9) | 19(79.2%) | |
Group D (severe group, much higher dose) | 22 | 8.1(6.6–12.1) | 8(36.4%) | 6.3(5.8–6.8) | 19(86.4%) | 5.9(5.1–6.6) | 20(90.9%) | |
P | <0.01 | <0.01 | 0.24 | 0.15 | 0.72 | 0.18 | ||